Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Here's an example: chances are if Merck or Amgen had been running our Phase II there would have been a protocol in the trial design excluding patients with implants and thereby we would have avoided the clinical hold setback. Between lack of expertise in running trial and O'Connors blatant greed and putting his own financial interests above his investors and patients, valuable time and resources were wasted.